Checkpoint Immunotherapy’s Growing Pains Show At ASCO
Executive Summary
Data presented at the 2014 ASCO annual meeting support expansion beyond the melanoma launch pad into multiple tumor types. Some of the data, however, let oncologists down and show that much more work is needed to deploy members of the checkpoint family to full effect.